Payment overview · 2025
General Payments
$10,113.51
207 reported records · 31 companies
Healthcare provider profile · identity verified
Bogdan Nedelescu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WORCESTER, MA · NPI 1699732800
Verified facts
What the public records show
CMS Open Payments records show Bogdan Nedelescu, M.D. received $10,113.51 in general payments during 2025 across 207 reported records.
Lilly USA, LLC accounted for 49.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Gemtesa, Ingrezza, Jardiance, Mounjaro, Nuplazid, Rexulti, Trelegy Ellipta, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Nuplazid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Biktarvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 429 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1730 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $5,026.14 | 49.7% | 27 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $697.78 | 6.9% | 19 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $572.96 | 5.7% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $490.31 | 4.8% | 17 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $420.55 | 4.2% | 13 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $355.59 | 3.5% | 11 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $300.11 | 3.0% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $228.36 | 2.3% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $199.56 | 2.0% | 9 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $190.38 | 1.9% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $168.12 | 1.7% | 11 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $158.67 | 1.6% | 8 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $155.84 | 1.5% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $122.11 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $113.03 | 1.1% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $107.18 | 1.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $95.26 | 0.9% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $94.95 | 0.9% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $91.25 | 0.9% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $78.78 | 0.8% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$73.60 | 0.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.46 | 0.7% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$48.22 | 0.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.03 | 0.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $39.41 | 0.4% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.44 | 0.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.98 | 0.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $30.32 | 0.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.57 | 0.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $23.35 | 0.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.20 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,492.76 | 196 |
| Consulting Fee | $4,050.00 | 2 |
| Travel and Lodging | $459.26 | 8 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $4,729.07 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $457.53 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $449.45 | 15 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $385.89 | 11 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $355.59 | 11 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $342.61 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $282.55 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $282.55 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $228.36 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $199.56 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $190.38 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $168.12 | 11 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $158.67 | 8 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $125.01 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $122.11 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $118.86 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $107.18 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $102.58 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $94.95 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $91.25 | 4 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $73.60 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $70.64 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $70.64 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $70.50 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $70.46 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $68.61 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $57.72 | 3 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $48.22 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $42.03 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.03 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $39.41 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $37.44 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $30.32 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1730 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 241 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 429 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 209 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 140 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
88 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
241 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
140 | 16 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
165 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
429 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
209 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
197 | 22 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1730 | 130 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
202 | 37 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 3841 | 349 |
| Gabapentin | Gabapentin | 2439 | 199 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2273 | 170 |
| Furosemide | Furosemide | 2100 | 179 |
| Trazodone Hcl | Trazodone Hcl | 2062 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 1885 | 185 |
| Lisinopril | Lisinopril | 1787 | 184 |
| Eliquis | Apixaban | 1730 | 130 |
| Metoprolol Succinate | Metoprolol Succinate | 1614 | 169 |
| Sertraline Hcl | Sertraline Hcl | 1460 | 126 |
| Metformin Hcl | Metformin Hcl | 1431 | 131 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1421 | 114 |
| Mirtazapine | Mirtazapine | 1176 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1155 | 127 |
| Omeprazole | Omeprazole | 1097 | 141 |
| Pantoprazole Sodium | Pantoprazole Sodium | 978 | 120 |
| Losartan Potassium | Losartan Potassium | 957 | 108 |
| Quetiapine Fumarate | Quetiapine Fumarate | 813 | 71 |
| Potassium Chloride | Potassium Chloride | 745 | 51 |
| Olanzapine | Olanzapine | 731 | 63 |
| Donepezil Hcl | Donepezil Hcl | 673 | 70 |
| Famotidine | Famotidine | 659 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 637 | 42 |
| Memantine Hcl | Memantine Hcl | 633 | 46 |
| Levetiracetam | Levetiracetam | 570 | 44 |
| Simvastatin | Simvastatin | 542 | 45 |
| Risperidone | Risperidone | 526 | 42 |
| Allopurinol | Allopurinol | 462 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 460 | 49 |
| Divalproex Sodium | Divalproex Sodium | 444 | 48 |
| Baclofen | Baclofen | 435 | 29 |
| Jardiance | Empagliflozin | 429 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 428 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 416 | 43 |
| Warfarin Sodium | Warfarin Sodium | 397 | 18 |
| Aripiprazole | Aripiprazole | 395 | 30 |
| Spironolactone | Spironolactone | 395 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 375 | 44 |
| Finasteride | Finasteride | 320 | 43 |
| Carvedilol | Carvedilol | 316 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 307 | 26 |
| Atenolol | Atenolol | 305 | 34 |
| Lamotrigine | Lamotrigine | 303 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 300 | 71 |
| Torsemide | Torsemide | 300 | 26 |
| Ezetimibe | Ezetimibe | 282 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 281 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 281 | 45 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 263 | 24 |
| Buspirone Hcl | Buspirone Hcl | 262 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 257 | 68 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 249 | 25 |
| Farxiga | Dapagliflozin Propanediol | 241 | 17 |
| Clozapine | Clozapine | 236 | 18 |
| Bupropion Xl | Bupropion Hcl | 234 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 231 | 23 |
| Clonazepam | Clonazepam | 218 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 28 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 209 | 98 |
| Mounjaro | Tirzepatide | 209 | 31 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 202 | 37 |
| Trulicity | Dulaglutide | 197 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 194 | 84 |
| Haloperidol | Haloperidol | 192 | 18 |
| Montelukast Sodium | Montelukast Sodium | 187 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 187 | 59 |
| Myrbetriq | Mirabegron | 183 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 180 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 174 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 166 | 31 |
| Xarelto | Rivaroxaban | 165 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 164 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 163 | 18 |
| Midodrine Hcl | Midodrine Hcl | 159 | 25 |
| Nystatin | Nystatin | 158 | 69 |
| Prednisone | Prednisone | 155 | 27 |
| Lorazepam | Lorazepam | 148 | 41 |
| Paroxetine Hcl | Paroxetine Hcl | 147 | 13 |
| Metformin Hcl Er | Metformin Hcl | 146 | 26 |
| Hydrocortisone | Hydrocortisone | 144 | 22 |
| Ibuprofen | Ibuprofen | 143 | 40 |
| Amiodarone Hcl | Amiodarone Hcl | 141 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 140 | 28 |
| Clonidine Hcl | Clonidine Hcl | 140 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 140 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 140 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 134 | 53 |
| Lactulose | Lactulose | 129 | 31 |
| Propranolol Hcl | Propranolol Hcl | 129 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 127 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 124 | 74 |
| Ziprasidone Hcl | Ziprasidone Hcl | 123 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 117 | 16 |
| Humalog | Insulin Lispro | 117 | 30 |
| Latanoprost | Latanoprost | 116 | 28 |
| Ranolazine Er | Ranolazine | 116 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 114 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 111 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 110 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 109 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 104 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 102 | 23 |
| Oxcarbazepine | Oxcarbazepine | 101 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 98 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 93 | 25 |
| Tramadol Hcl | Tramadol Hcl | 90 | 22 |
| Valsartan | Valsartan | 90 | 13 |
| Brilinta | Ticagrelor | 88 | suppressed |
| Cephalexin | Cephalexin | 87 | 53 |
| Bupropion Hcl | Bupropion Hcl | 84 | suppressed |
| Chlorthalidone | Chlorthalidone | 84 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 82 | 11 |
| Nyamyc | Nystatin | 82 | 25 |
| Lithium Carbonate | Lithium Carbonate | 80 | suppressed |
| Levofloxacin | Levofloxacin | 79 | 45 |
| Loperamide | Loperamide Hcl | 79 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 29 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 77 | 77 |
| Lidocaine | Lidocaine | 75 | 15 |
| Movantik | Naloxegol Oxalate | 75 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 74 | 30 |
| Enoxaparin Sodium | Enoxaparin Sodium | 73 | 15 |
| Fentanyl | Fentanyl | 73 | suppressed |
| Azithromycin | Azithromycin | 72 | 44 |
| Nuplazid | Pimavanserin Tartrate | 72 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 72 | suppressed |
| Digoxin | Digoxin | 71 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 71 | 18 |
| Ozempic | Semaglutide | 70 | 15 |
| Topiramate | Topiramate | 70 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 69 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 68 | suppressed |
| Bumetanide | Bumetanide | 67 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 64 | suppressed |
| Amoxicillin | Amoxicillin | 63 | 34 |
| Linzess | Linaclotide | 63 | 14 |
| Methocarbamol | Methocarbamol | 63 | 13 |
| Lovastatin | Lovastatin | 61 | suppressed |
| Methimazole | Methimazole | 60 | suppressed |
| Vascepa | Icosapent Ethyl | 60 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 59 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 58 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | suppressed |
| Colchicine | Colchicine | 58 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 57 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 37 |
| Nifedipine Er | Nifedipine | 56 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | suppressed |
| Mupirocin | Mupirocin | 54 | 24 |
| Synthroid | Levothyroxine Sodium | 53 | suppressed |
| Ursodiol | Ursodiol | 53 | suppressed |
| Jantoven | Warfarin Sodium | 52 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 52 | suppressed |
| Procrit | Epoetin Alfa | 52 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 50 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 50 | 14 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 49 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 48 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 48 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 48 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 47 | suppressed |
| Irbesartan | Irbesartan | 47 | suppressed |
| Lumigan | Bimatoprost | 47 | suppressed |
| Scopolamine | Scopolamine | 47 | suppressed |
| Erythromycin | Erythromycin Base | 46 | 27 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 46 | suppressed |
| Alprazolam | Alprazolam | 45 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 45 | suppressed |
| Permethrin | Permethrin | 45 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Sucralfate | Sucralfate | 43 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 43 | 15 |
| Ertapenem | Ertapenem Sodium | 42 | 14 |
| Zenpep | Lipase/Protease/Amylase | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 30 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 40 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 40 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 40 | suppressed |
| Perphenazine | Perphenazine | 40 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Nystop | Nystatin | 39 | 23 |
| Insulin Lispro | Insulin Lispro | 38 | suppressed |
| Ketoconazole | Ketoconazole | 38 | 22 |
| Metronidazole | Metronidazole | 38 | 15 |
| Calcitriol | Calcitriol | 37 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | suppressed |
| Carbamazepine | Carbamazepine | 36 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 36 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 34 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 34 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Ramelteon | Ramelteon | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Amantadine | Amantadine Hcl | 32 | suppressed |
| Folic Acid | Folic Acid | 32 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 20 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Rexulti | Brexpiprazole | 32 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 31 |
| Metolazone | Metolazone | 31 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 30 | suppressed |
| Restasis | Cyclosporine | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 20 |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 29 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 28 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | 17 |
| Tresiba | Insulin Degludec | 27 | suppressed |
| Budesonide | Budesonide | 26 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 26 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 25 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Acetazolamide | Acetazolamide | 23 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 23 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Roflumilast | Roflumilast | 23 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 14 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Exemestane | Exemestane | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Acetylcysteine | Acetylcysteine | 21 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 21 | suppressed |
| Dexamethasone | Dexamethasone | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 20 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 12 |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 19 | suppressed |
| Hydroxyurea | Hydroxyurea | 19 | suppressed |
| Ingrezza | Valbenazine Tosylate | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Zerbaxa | Ceftolozane/Tazobactam | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 14 |
| Naproxen | Naproxen | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Tacrolimus | Tacrolimus | 18 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ceftazidime | Ceftazidime | 17 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 17 | suppressed |
| Mirabegron Er | Mirabegron | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Dalfampridine Er | Dalfampridine | 16 | suppressed |
| Enbrel Sureclick | Etanercept | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Olanzapine Odt | Olanzapine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 16 | 12 |
| Clotrimazole | Clotrimazole | 15 | 11 |
| Clozapine Odt | Clozapine | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Paliperidone Er | Paliperidone | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Rytary | Carbidopa/Levodopa | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Vancomycin Hcl-0.9% Nacl | Vancomycin/0.9 % Sod Chloride | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Alclometasone Dipropionate | Alclometasone Dipropionate | 11 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,113.51 · 207 records | Lilly USA, LLC | AIRSUPRA, AMVUTTRA, AMYVID, AREXVY, AUSTEDO XR, CAPLYTA, Cologuard Collection Kit, DUPIXENT, ELIQUIS, ENTRESTO, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, IBSRELA, INGREZZA, INSPIRE, INTELLIS ADAPTIVESTIM, JARDIANCE, KISUNLA, Kerendia, LEQEMBI, LEQVIO, MOUNJARO, NUPLAZID, NURTEC ODT, OTEZLA, Ohtuvayre, QULIPTA, REPATHA, REXULTI, SHINGRIX, SPRAVATO, TEZSPIRE, TRELEGY ELLIPTA, TZIELD, UBRELVY, UZEDY, VALTOCO, VOQUEZNA, VOWST, VRAYLAR, ZENPEP, ZEPBOUND | 27 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error